As a liquid biopsy company, LIQOMICS is transforming oncology with non-invasive ctDNA analysis for cancer monitoring and treatment optimization. Our circulating tumor DNA (ctDNA) tests provide: ✔ Ultra-sensitive detection of minimal residual disease (MRD) ✔ Real-time insights into tumor genetics from a simple blood draw ✔ Exceptional precision for tracking treatment response We empower the hematology and oncology ecosystem to make data-driven decisions for lymphomas, solid tumors, and other malignancies by eliminating the need for invasive biopsies. Discover how our liquid biopsy technology is redefining cancer management.
| Website | https://liqomics.com |
| Employees | 8 (6 on RocketReach) |
| Founded | 2021 |
| Address | Neurather Ring 1, Cologne, North Rhine-Westphalia 51063, DE |
| Industry | Medical and Diagnostic Laboratories |
| Keywords | Circulating Tumor Dna, Liquid Biopsy, Cancer Genetics, Precision Oncology, Personalized Cancer Medicine, Cancer Biomarkers, Oncology Diagnostics, Molecular Diagnostics |
| Competitors | Roche, Thermo Fisher Scientific, Agilent Technologies, Illumina, MilliporeSigma, PerkinElmer, Inc., Bio-Rad Laboratories, QIAGEN, Bruker, SCIEX +33 more (view full list) |
Looking for a particular LIQOMICS employee's phone or email?
Sven Borchmann is the Founder and CEO of LIQOMICS.
6 people are employed at LIQOMICS.
LIQOMICS is based in Cologne, North Rhine-Westphalia.